<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/DHEA.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:34:07 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="2837008">
<meta name="Category" content="Supp">
<meta name="Article" content="DHEA">
<title>Dehidroepiandrosterona-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">Dehidroepiandrosterona (DHEA)</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="DHEA.htm">Volver al art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Weksler ME. Hormone replacement for men. Br Med J 1996;312:859-60
[editorial].</li>

<li class="Ref">Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone.
Lancet 1994;343:1479-81.</li>

<li class="Ref">Stomati M, Rubino S, Spinetti A, et al. Endocrine, neuroendocrine and
behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal
women. Gynecol Endocrinol 1999;13:15-25.</li>

<li class="Ref">Labrie F, Belanger A, Simard J, et al. DHEA and peripheral androgen and
estrogen formation: Intracrinology. <em>Ann NY Acad Sci</em> 1995;774:16-28.</li>

<li class="Ref">Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment
of erectile dysfunction: a prospective, double-blind randomized, placebo-controlled study.
<em>Urology</em> 1999;53:590-5.</li>

<li class="Ref">Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month
percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. <em>J
Endocrinol</em> 1996;150:S43-50.</li>

<li class="Ref">Nestler JE, Barlasini CO, Clore JN, et al. Dehydroepiandrosterone reduces
serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in
normal men. <em>J Clin Endocrinol Metab</em> 1988;66:57-61.</li>

<li class="Ref">Welle S, Jozefowicz R, Statt M. Failure of DHEA to influence energy and
protein metabolism in humans. <em>J Clin Endocrinol Metab</em> 1990;71:1259.</li>

<li class="Ref">Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of
dehydroepiandrosterone in obese men. <em>Int J Obes</em> 1990;14:457-63.</li>

<li class="Ref">Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al. Dehydroepiandrosterone in
morbidly obese adolescents: effects on weight, body composition, lipids, and insulin
resistance. <em>Metabolism</em> 1996;45:1101-15.</li>

<li class="Ref">Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
<em>Ann NY Acad Sci</em> 1995;774:128-42.</li>

<li class="Ref">Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month
percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. <em>J
Endocrinol</em> 1996;150:S43-50.</li>

<li class="Ref">Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
<em>Ann NY Acad Sci</em> 1995;774:128-42.</li>

<li class="Ref">Mortola J, Yen SSC. The effects of dehydroepiandrosterone on
endocrine-metabolic parameters in postmenopausal women. <em>J Clin Endocrinol Metab</em>
1990;71:695-704.</li>

<li class="Ref">Khorram O, Vu L, Yen SS. Activation of immune function by
dehydroepiandrosterone (DHEA) in age-advanced men. <em>J Gerontol A Biol Sci Med Sci</em>
1997;52:M1-7.</li>

<li class="Ref">Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in
physiologic doses modulates immune function in postmenopausal women. <em>Am J Obstet
Gynecol</em> 1993;169:1536-9.</li>

<li class="Ref">Jessee RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human
platelet aggregation in vitro and in vivo. <em>Ann NY Acad Sci</em> 1995;29:281-90.</li>

<li class="Ref">Schaefer C, Friedman G, Ettinger B, et al. Dehydroepiandrosterone sulfate
(DHEAS), angina, and fatal ischemic heart disease. <em>Am J Epidemiol</em>
1996;143(11suppl):S69 [abstr #274].</li>

<li class="Ref">Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and
cardiovascular disease. <em>Ann NY Acad Sci</em> 1995;774:259-70.</li>

<li class="Ref">Johannes CB, Stellato RK, Feldman HA, et al. Relation of
dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk
factors in women: longitudinal results from the Massachusetts Women&#8217;s Health Study. <em>
J Clin Epidemiol</em> 1999;52:95-103.</li>

<li class="Ref">Mortola J, Yen SSC. The effects of dehydroepiandrosterone on
endocrine-metabolic parameters in postmenopausal women. <em>J Clin Endocrinol Metab</em>
1990;71:695-704.</li>

<li class="Ref">Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
<em>Ann NY Acad Sci</em> 1995;774:128-42.</li>

<li class="Ref">Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone
replacement in aging humans. <em>J Clin Endocrinol Metab</em> 1999;84:1527-33.</li>

<li class="Ref">Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA
sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. <em>Proc Natl
Acad Sci U S A</em> 2000;97:4279-84.</li>

<li class="Ref">Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with
systemic lupus erythematosus. <em>Arthritis Rheum</em> 1987;30:241-8.</li>

<li class="Ref">van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in
systemic lupus erythematosus. <em>Arthritis Rheum</em> 1995;38:1826-31.</li>

<li class="Ref">van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of
systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
<em>J Rheumatol</em> 1998;25:285-9.</li>

<li class="Ref">Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of DHEA
in men and women of advancing age. <em>J Clin Endorcrionol Metab</em> 1994;78:1360.</li>

<li class="Ref">Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major
depression with dehydroepiandrosterone. <em>Am J Psychiatry</em> 1999;156:646-9.</li>

<li class="Ref">Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of
midlife dysthymia. <em>Biol Psychiatry</em> 1999;45:1533-41.</li>

<li class="Ref">Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological
dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly
women and men. <em>J Clin Endocrinol Metab</em> 1997;82:2263-7.</li>

<li class="Ref">Gaby AR. Research review. <em>Nutr Healing,</em> 1997;Jun: 8.</li>

<li class="Ref">Araghiniknam J, Chung S, Nelson-White T, et al. Antioxidant activity of
dioscorea and dehydroepiandrosterone (DHEA) in older humans. <em>Life Sci</em>
1996;59:147&#8211;57.</li>

<li class="Ref">Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone.
<em>Lancet</em> 1994;343:1479&#8211;81.</li>

<li class="Ref">Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement
in women with adrenal insufficiency. <em>N Engl J Med</em> 1999;341:1013&#8211;20.</li>

<li class="Ref">Gebre-Medhin G, Husebye ES, Mallmin H, et al. Oral dehydroepiandrosterone
(DHEA) replacement therapy in women with Addison&#8217;s disease. <em>Clin Endocrinol
(Oxf)</em> 2000;52:775&#8211;80.</li>

<li class="Ref">Barrett-Connor E, von M&#252;hlen D, Laughlin GA, Kripke A. Endogenous levels
of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed
mood in older women: The Rancho Bernardo Study. <em>J Am Geriatr Soc</em>
1999;47:685&#8211;91.</li>

<li class="Ref">Heinz A, Weingartner H, George D, et al. Severity of depression in abstinent
alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate
concentrations. <em>Psychiatry Res</em> 1999;89:97&#8211;106.</li>

<li class="Ref">Heuser I, Deuschle M, Luppa P, et al. Increased diurnal plasma concentrations
of dehydroepiandrosterone in depressed patients. <em>J Clin Endocrinol Metab</em>
1998;83:3130&#8211;3.</li>

<li class="Ref">Azuma T, Nagai Y, Saito T, et al. The effect of dehydroepiandrosterone sulfate
administration to patients with multi-infarct dementia. <em>J Neurol Sci</em>
1999;162:69&#8211;73.</li>

<li class="Ref">Ferrando SJ, Rabkin JG, Poretsky L. Dehydroepiandrosterone sulfate (DHEAS) and
testosterone: Relation to HIV illness stage and progression over one year. <em>J Acquir Immune
Defic Syndr</em> 1999;22:146&#8211;54.</li>

<li class="Ref">Louviselli A, Pisanu P, Cossu E, et al. Low levels of dehydroepiandrosterone
sulfate in adult males with insulin-dependent diabetes mellitus. <em>Minerva Endocrinol</em>
1994;19:113&#8211;9.</li>

<li class="Ref">Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of
dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in
proportion to the severity. <em>J Clin Endocrinol Metab</em> 2000;85:1834&#8211;40.</li>

<li class="Ref">K&#252;mpfel T, Then Bergh F, Friess E, et al. Dehydroepiandrosterone response
to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing
hormone test in patients with multiple sclerosis. <em>Neuroendocrinology</em>
1999;70:431&#8211;8.</li>

<li class="Ref">Weinstein RE, Lobocki CA, Gravett S, et al. Decreased adrenal sex steroid in
the absence of glucocorticoid suppression in postmenopausal asthmatic women. <em>J Allergy
Clin Immunol</em> 1996;97:1&#8211;8.</li>

<li class="Ref">Dunn PJ; Mahood CB; Speed JF; Jury DR. Dehydroepiandrosterone sulphate
concentrations in asthmatic patients: pilot study. <em>N Z Med J</em>
1984;97:805&#8211;8.</li>

<li class="Ref">Kuratsune H, Yamaguti K, Sawada M, et al. Dehydroepiandrosterone sulfate
deficiency in chronic fatigue syndrome. <em>Int J Mol Med</em> 1998;1:143&#8211;6.</li>

<li class="Ref">De Becker P, De Meirleir K, Joos E, et al. Dehydroepiandorsterone (DHEA)
response to i.v. ACTH in patients with chronic fatigue syndrome. <em>Horm Metab Res</em>
1999;31:18&#8211;21.</li>

<li class="Ref">Khalkhali-Ellis Z, Moore TL, Hendrix MJ. <em>Clin Exp Rheumatol</em>
1998;16:753&#8211;6.</li>

<li class="Ref">Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone
sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone
density. <em>Ann Rheum Dis</em> 1993;52:211&#8211;4.</li>

<li class="Ref">Mateo L, Nolla JM, Bonnin MR, et al. Sex hormone status and bone mineral
density in men with rheumatoid arthritis. <em>J Rheumatol</em> 1995;22:1455&#8211;60.</li>

<li class="Ref">Gaby AR. Dehydroepiandrosterone: biological effects and clinical significance.
<em>Altern Med Rev</em> 1996;1:60&#8211;9 [review].</li>

<li class="Ref">Heikkila R, Aho K, Heliovaara M, et al. Serum androgen-anabolic hormones and
the risk of rheumatoid arthritis. <em>Ann Rheum Dis</em> 1998;57:281&#8211;5.</li>

<li class="Ref">Mileva Zh, Maleeva A, Khristov G. Androstenedione, DHEA sulfate, cortisol,
aldosterone and testosterone in bronchial asthma patients. <em>Vutr Boles</em>.
1990;29:84&#8211;7 [in Bulgarian].</li>

<li class="Ref">Reiter WJ, Pycha A, Schatzl G, et al. Serum dehydroepiandrosterone sulfate
concentrations in men with erectile dysfunction. <em>Urology</em> 2000;55:755&#8211;8.</li>

<li class="Ref">Hillen T, Lun A, Reischies FM, et al. DHEA-S plasma levels and incidence of
Alzheimer&#8217;s disease. <em>Biol Psychiatry</em> 2000;47:161&#8211;3.</li>

<li class="Ref">Nasman B, Olsson T, Backstrom T, et al. Serum dehydroepiandrosterone sulfate
in Alzheimer&#8217;s disease and in multi-infarct dementia. <em>Biol Psychiatry</em>
1991;30:684&#8211;90.</li>

<li class="Ref">Sunderland T, Merril CR, Harrington MG, et al. Reduced plasma
dehydroepiandrosterone concentrations in Alzheimer&#8217;s disease. <em>Lancet</em>
1989;2:570.</li>

<li class="Ref">Yanase T, Fukahori M, Taniguchi S, et al. Serum dehydroepiandrosterone (DHEA)
and DHEA-sulfate (DHEA-S) in Alzheimer&#8217;s disease and in cerebrovascular dementia. <em>
Endocr J</em> 1996;43:119&#8211;23.</li>

<li class="Ref">Birkenhager-Gillesse EG, Derksen J, Lagaay AM. Dehydroepiandrosterone sulphate
(DHEAS) in the oldest old, aged 85 and over. <em>Ann N Y Acad Sci</em>
1994;719:543&#8211;52.</li>

<li class="Ref">Schneider LS, Hinsey M, Lyness S. Plasma dehydroepiandrosterone sulfate in
Alzheimer&#8217;s disease. <em>Biol Psychiatry</em> 1992;31:205&#8211;8.</li>

<li class="Ref">Gaby AR. Research review. <em>Nutr Healing,</em> 1996;Jan:7.</li>

<li class="Ref">Casson PR, Buster JE. DHEA replacement after menopause: HRT 200 or nostrum of
the &#8216;90s? <em>Contemporary OB/GYN</em> 1997;Apr:119&#8211;33.</li>

<li class="Ref">Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal
androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in
healthy young females after dexamethasone suppression. <em>J Clin Endocrinol Metab</em>
1998;83:1928&#8211;34.</li>

<li class="Ref">Parasrampuria J, Schwartz K, Petesch R. Quality control of
dehydroepiandrosterone dietary supplement products. <em>JAMA</em> 1998;280:1565 [letter].</li>

<li class="Ref">van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of
systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
<em>J Rheumatol</em> 1998;25:285&#8211;9.</li>

<li class="Ref">Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced
mania. <em>Biol Psychiatry</em> 1999;45:241&#8211;2.</li>

<li class="Ref">Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological
dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly
women and men. <em>J Clin Endocrinol Metab</em> 1997;82:2263&#8211;7.</li>

<li class="Ref">Bowers LD. Oral dehydroepiandrosterone supplementation can increase the
testosterone/epitestosterone ratio. <em>Clin Chem</em> 1999;45:295&#8211;6.</li>

<li class="Ref">Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of DHEA
in men and women of advancing age. <em>J Clin Endocrinol Metab</em> 1994;78:1360.</li>

<li class="Ref">Orner GA, Mathews C, Hendricks JD, et al. Dehydroepiandrosterone is a complete
hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in
rainbow trout. <em>Carcinogenesis</em> 1995;16:2893&#8211;8.</li>

<li class="Ref">Metzger C, Mayer D, Hoffmann H, et al. Sequential appearance and
ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and
female rats treated with dehydroepiandrosterone. <em>Toxicol Pathol</em>
1995;23:591&#8211;605.</li>

<li class="Ref">McNeil C. Potential drug DHEA hits snags on way to clinic. <em>J Natl Cancer
Inst</em> 1997;89:681&#8211;3.</li>

<li class="Ref">Jones JA, Nguyen A, Strab M, et al. Use of DHEA in a patient with advanced
prostate cancer: a case report and review. <em>Urology</em> 1997;50:784&#8211;8.</li>

<li class="Ref">Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma
concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with
primary operable breast cancer. <em>Cancer Res</em> 1981;41:3360&#8211;3.</li>

<li class="Ref">Helzlsouer KJ, Gordon GB, Alberg AJ, et al. Relationship of prediagnostic
serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of
developing premenopausal breast cancer. <em>Cancer Res</em> 1992;52:1&#8211;4.</li>

<li class="Ref">Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum
estrogen and androgen levels to breast cancer risk. <em>Cancer Epidemiol Biomarkers Prev</em>
1996;5:533&#8211;9.</li>

<li class="Ref">Gordon GB, Bush TL, Helzlsouer KJ, et al. Relationship of serum levels of
dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing
postmenopausal breast cancer. <em>Cancer Res</em> 1990;50:3859&#8211;62.</li>

<li class="Ref">Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause
and subsequent breast cancer. <em>J Natl Cancer Inst</em> 1996;88:291&#8211;6.</li>

<li class="Ref">Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels
and risk of breast cancer in postmenopausal women. <em>J Natl Cancer Inst</em>
1998;90:1292&#8211;9.</li>

<li class="Ref">Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma
concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with
primary operable breast cancer. <em>Cancer Res</em> 1981;41:3360&#8211;3.</li>

<li class="Ref">Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, et al. Relation of serum levels
of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal
women. <em>Am J Epidemiol</em> 1997;145:1030&#8211;8.</li>

<li class="Ref">Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and
breast cancer risk. <em>Cancer Res</em> 1990;50:6571&#8211;4.</li>

<li class="Ref">Bernstein L, Ross RK, Pike MC, et al. Hormone levels in older women: a study
of post-menopausal breast cancer patients and healthy population controls. <em>Br J
Cancer</em> 1990;61:298&#8211;302.</li>

<li class="Ref">Johannes CB, Stellato RK, Feldman HA, et al. Relation of
dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk
factors in women: longitudinal results from the Massachusetts Women&#8217;s Health Study. <em>
J Clin Epidemiol</em> 1999;52:95&#8211;103.</li>

<li class="Ref">Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment
with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body
composition and muscle strength in age-advanced men and women. <em>Clin Endocrinol (Oxf)</em>
1998;49:421&#8211;32.</li>

<li class="Ref">Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid
hormones and the development of ovarian cancer. <em>JAMA</em> 1995;274:1926&#8211;30.</li>

<li class="Ref">Heinonen PK, Koivula T, Pystynen P. Decreased serum level of
dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. <em>Gynecol Obstet
Invest</em> 1987;23:271&#8211;4.</li>

<li class="Ref">Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H
(A vy/a) mice by long-term treatment with dehydroepiandrosterone. <em>Cancer Res</em>
1979;39:1129&#8211;32.</li>

<li class="Ref">Sahelian R. New supplements and unknown, long-term consequences. <em>Am J
Natural Med</em> 1997;4:8 [editorial].</li>

<li class="Ref">Schunkert H, Hense H-W, Andus T, et al. Relation between
dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. <em>Am
J Hypertens</em> 1999;12:1140&#8211;3.</li>

<li class="Ref">Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone
as coronary risk factors in the Helsinki Heart Study. <em>Atherosclerosis</em>
1994;105:191&#8211;200.</li>

<li class="Ref">Kiechl S, Willeit J, Bonora E, et al. No association between
dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population
study (Bruneck Study). <em>Arterioscler Thromb Vasc Biol</em> 2000;20:1094&#8211;100.</li>

<li class="Ref">Suzuki M, Kanazawa A, Hasegawa M, et al. A close association between insulin
resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. <em>
Endocr J</em> 1999;46:521&#8211;8.</li>

<li class="Ref">Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal
dehydroepiandrosterone administration increases free insulin-like growth factor-I and
decreases high-density lipoprotein: a six-month trial. <em>Fertil Steril</em>
1998;70:107&#8211;10.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/DHEA.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:34:07 GMT -->
</html>

